Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

  • January 2019 •
  • 14 pages •
  • Report ID: 5779916 •
  • Format: PDF
Overview
A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

Major marketed drugs for HR+/HER2- breast cancer are discussed, including the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. Key late-phase pipeline drugs are also covered, with a focus on Novartis’s alpelisib.